Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks	5	783
Total, all-cause mortality	SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks	4	793
Total, all-cause mortality	ZONDA - Benralizumab 30 mg q.4 Weeks	0	49
Total, all-cause mortality	ZONDA - Benralizumab 30 mg q.8 Weeks	1	49
Total, other adverse events	SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks	415	783
Total, other adverse events	SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks	409	793
Total, other adverse events	ZONDA - Benralizumab 30 mg q.4 Weeks	33	49
Total, other adverse events	ZONDA - Benralizumab 30 mg q.8 Weeks	38	49
Total, serious adverse events	SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks	102	783
Total, serious adverse events	SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks	94	793
Total, serious adverse events	ZONDA - Benralizumab 30 mg q.4 Weeks	10	49
Total, serious adverse events	ZONDA - Benralizumab 30 mg q.8 Weeks	9	49

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02258542/event-totals